Furthermore, lower levels of MICA expression were associated with a higher risk of HCC development in patients, and shedding of MICA is known to interdict its action6, indicating that the hypofunction of anti-cancer immunity is a suitable target for pharmacotherapy via manipulating MICA expression. Here, MICA is linked to hepatocellular carcinoma.